A promising new treatment strategy for hepatoblastoma
A combination therapy of vincristine, irinotecan and panobinostat, tested in high-risk, relapsed or refractory HB spheroids, decreased tumour marker levels.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
A combination therapy of vincristine, irinotecan and panobinostat, tested in high-risk, relapsed or refractory HB spheroids, decreased tumour marker levels.
Many exciting developments are expected to take place in immunotherapy and oncology in the next few years. We had the privilege of discussing the opportunities of various cell therapies with Dr Suresh Nair, Physician in Chief, who elucidates how Lehigh Valley Topper Cancer Institute is directing research towards better treatments,…
New immunotherapies may be developed for patients with HCC associated with steatotic liver disease, with TREM1 suggested as a target.
Using tumour organoids, researchers identified that overexpression of Engrailed-1 blocked genes associated with natural cell death.
Low-dose positron emission mammography (PEM) has a high sensitivity for detecting cancer and reduces the likelihood of false positives.
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
A novel cellular mechanism has been uncovered with the use of CRISPR gene-tiling technology, which could advance oncologic therapies.
For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
A new blood panel test reports the tumour fraction and the tumour type of prostate cancer with a high level of accuracy.
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
A discovery about the mutated protein DECTIN-1, that limits the production of T regulatory cells, could lead to more effective drugs.